Sellas Life Sciences Group Inc (SLS)

Jan 31, 2025

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World

Jan 31, 2025

Jan 30, 2025

Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register

Jan 30, 2025

Jan 29, 2025

SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow

Jan 29, 2025

Jan 29, 2025

Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL

Jan 29, 2025

Jan 28, 2025

SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa

Jan 28, 2025

Jan 28, 2025

SELLAS secures $25 million in registered direct offering - MSN

Jan 28, 2025

Jan 28, 2025

SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire

Jan 28, 2025

Jan 28, 2025

Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan

Jan 28, 2025

Jan 24, 2025

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - MarketBeat

Jan 24, 2025

Jan 24, 2025

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World

Jan 24, 2025

Jan 23, 2025

SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks

Jan 23, 2025

Jan 23, 2025

SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha

Jan 23, 2025

Jan 23, 2025

SELLAS Life Sciences Announces Positive Outcome of Interim - GlobeNewswire

Jan 23, 2025

Jan 23, 2025

SELLAS Phase 3 AML Trial Shows Promising 13.5-Month Survival Data, Double Historical Average - StockTitan

Jan 23, 2025

Jan 22, 2025

SLS Stock Quote Price and Forecast - CNN

Jan 22, 2025

Jan 18, 2025

SELLAS Life Sciences amends executive severance agreements - MSN

Jan 18, 2025

Jan 18, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - Defense World

Jan 18, 2025

Jan 17, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register

Jan 17, 2025

Jan 17, 2025

SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World

Jan 17, 2025

Jan 17, 2025

SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Australia

Jan 17, 2025

Jan 16, 2025

SELLAS Life Sciences Amends Severance for Key Executives - TipRanks

Jan 16, 2025

Jan 14, 2025

Analyze SELLAS Life Sciences Group Inc (NASDAQ: SLS) Before Investing. - Stocks Register

Jan 14, 2025

Jan 11, 2025

Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jan 11, 2025

Jan 08, 2025

SELLAS advances cancer drug trials, eyes key 2025 milestones - Investing.com

Jan 08, 2025

Jan 08, 2025

SELLAS advances cancer drug trials, eyes key 2025 milestones By Investing.com - Investing.com UK

Jan 08, 2025

Jan 08, 2025

SELLAS Announces Key Business Objectives for 2025 - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

SELLAS Life Sciences' Cancer Drug Shows 3x Better Survival Rate in Advanced Leukemia Study - StockTitan

Jan 08, 2025

Jan 04, 2025

State Street Corp Increases Stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jan 04, 2025

Jan 02, 2025

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - GlobeNewswire

Jan 02, 2025

Jan 02, 2025

SELLAS Life Sciences Announces 2025 Corporate Strategy Call with CEO and Cancer Expert - StockTitan

Jan 02, 2025

Dec 29, 2024

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December - MarketBeat

Dec 29, 2024

Dec 22, 2024

62,785 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by XTX Topco Ltd - Defense World

Dec 22, 2024

Dec 18, 2024

United Rentals (URI-N) QuotePress Release - The Globe and Mail

Dec 18, 2024

Dec 11, 2024

SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia - Marketscreener.com

Dec 11, 2024

Dec 10, 2024

SELLAS Life Sciences Advances Phase 3 AML Trial - TipRanks

Dec 10, 2024

Dec 10, 2024

SELLAS triggers interim analysis in AML trial - Investing.com

Dec 10, 2024

Dec 10, 2024

SELLAS triggers interim analysis in AML trial By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 10, 2024

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewswire

Dec 10, 2024

Dec 10, 2024

SELLAS Life Sciences Hits Major Milestone in Phase 3 AML Cancer Treatment Trial - StockTitan

Dec 10, 2024

Dec 10, 2024

SELLAS reports promising AML drug trial results By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 09, 2024

SELLAS reports promising AML drug trial results - Investing.com India

Dec 09, 2024

Dec 09, 2024

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - The Manila Times

Dec 09, 2024

Dec 09, 2024

SELLAS Announces Positive Overall Survival and Overall - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

SELLAS' SLS009 Triples Survival Time in Phase 2 AML Trial, Shows Breakthrough Response Rates - StockTitan

Dec 09, 2024

Dec 08, 2024

Anson Funds Management LP Purchases Shares of 793,835 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - MarketBeat

Dec 08, 2024

Nov 28, 2024

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers - Yahoo Finance

Nov 28, 2024

Nov 27, 2024

SELLAS Announces Positive Data from Preclinical Studies - GlobeNewswire

Nov 27, 2024

Nov 27, 2024

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor - The Bakersfield Californian

Nov 27, 2024